SniperFx

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • September 2022
  • August 2022
  • January 2022
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019

Categories

  • Bonds
  • Brokers News
  • Crypto
  • Forex
  • Forex Trading
  • News
  • Stocks
  • Technology
  • World
Subscribe
SniperFx SniperFx
SniperFx
  • Latest Updates
  • Bonds
  • Brokers News
  • Crypto
  • Forex
  • Forex Trading
  • Stocks
  • World
  • Stocks

GSK bets $2 billion on Bellus cough drug to soothe pipeline fears

  • April 18, 2023

GSK plans to buy Canada-based drug developer Bellus Health Inc in an all-cash deal for $2 billion as the British drugmaker expands its bet on respiratory therapies.

The move to replenish its pipeline comes as GSK investors fret about whether there is enough in the medicine cabinet to keep the momentum going into the next decade with expected loss of patent protection of one of its key compounds.

At the heart of the deal – announced by both companies on Tuesday – is the experimental drug, camlipixant, which is in late-stage development as a treatment for refractory chronic cough (RCC).

The condition can cause patients to cough more than 900 times a day for more than a year. Some 10 million patients globally suffer from it and so far, there are no approved therapies.

GSK’s offer of $14.75 per share is more than double Bellus’ closing price of $7.26 on the Nasdaq on Monday.

The Bellus deal expands GSK’s existing respiratory portfolio, including Nucala and Trelegy, which generated more than a combined 3 billion pounds ($3.73 billion) last year.

Camlipixant is up against Merck’s rival drug, gefapixant, for RCC patients.

Early in 2022, gefapixant was denied approval by the U.S. regulator, which sought more information on its effectiveness – but the U.S. drugmaker is expected to resubmit an application for another review later this year.

Still, some analysts say camlipixant – should both drugs be eventually approved – could emerge as preferred option with a superior safety profile.

Jefferies analysts estimated camlipixant could generate peak U.S. sales of $1.2 billion, in a note earlier this month.

DEAL FLURRY

Investors are particularly interested in GSK’s future plans, given the pending loss of patent protection in 2027 for dolutegravir, the compound that forms part of four GSK’s HIV treatments, which puts more than 5 billion pounds of sales at risk.

The company is leaning in part on the prospects of its own vaccine targeted at the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths a year, to at least partially offset that loss.

It has also announced a string of deals including a buyout of Affinivax and Sierra Oncology (NASDAQ:SRRA) to plug the gap.

Still, the company also has culled a handful of programmes from its pipeline in recent months and suffered setbacks in its marketed cancer drug portfolio.

Demand for its flagship blockbuster Shingrix vaccine is also expected to eventually saturate.

admin

Previous Article
  • News

‘Biggest mistake’ is not using tax loss harvesting Koinly head of tax

  • April 18, 2023
Read More
Next Article
  • News

USDJPY Brief results and immediate prospects

  • April 19, 2023
Read More
You May Also Like
Read More
  • Stocks

Eicher Motors shares surged following Jefferies’ bullish outlook and upgraded target price.

  • admin
  • September 26, 2023
Read More
  • Stocks

US employment commission sues UPS, alleging discrimination against deaf driver candidates

  • admin
  • September 23, 2023
Read More
  • Stocks

Obesity drugs by Novo Nordisk and Eli Lilly will impact the healthcare economy

  • admin
  • September 21, 2023
Read More
  • Stocks

European stock futures decline, and industrial production in Germany continues to decline.

  • admin
  • September 7, 2023
Read More
  • Stocks

Daimler Truck hits double-digit return on sales in industrial business

  • admin
  • August 1, 2023
Read More
  • Stocks

European stock futures flat; key eurozone growth, inflation data due

  • admin
  • July 31, 2023
Read More
  • Stocks

China’s video game player population rises to a record at end-June

  • admin
  • July 27, 2023
Read More
  • Stocks

Cryptoverse Ripple effect as explosive XRP leads market charge

  • admin
  • July 25, 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts
  • Eicher Motors shares surged following Jefferies’ bullish outlook and upgraded target price.
  • The USD/THB faces some side-line trading in the near term (UOB).
  • The euro extends its decline to fresh six-month lows near 1.0570
  • Bitcoin miners strategize for survival amid rising costs and upcoming halving
  • Awareness of non-banks as an option is on the rise.
SniperFx
  • Home
  • About Us
  • Contact
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
Forex & Crypto Updates

Input your search keywords and press Enter.